Free Trial
→ Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps (From Weiss Ratings) (Ad) Buy RNA Stock  Free RNA Stock Alerts

Avidity Biosciences (RNA) Financials

Avidity Biosciences logo
$32.28 +0.08 (+0.25%)
Closing price 05/5/2025 04:00 PM Eastern
Extended Trading
$30.00 -2.28 (-7.06%)
As of 04:44 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Avidity Biosciences

Annual Income Statements for Avidity Biosciences

This table shows Avidity Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -11 -25 -44 -118 -174 -212 -322
Consolidated Net Income / (Loss)		 -11 -25 -44 -118 -174 -212 -322
Net Income / (Loss) Continuing Operations		 -11 -25 -44 -118 -174 -212 -322
Total Pre-Tax Income 		-10 -25 -44 -118 -174 -212 -322
Total Operating Income		 -10 -17 -44 -118 -179 -236 -379
Total Gross Profit		 0.38 2.32 6.79 9.33 9.22 9.56 11
Total Revenue		 0.38 2.32 6.79 9.33 9.22 9.56 11
Operating Revenue		 0.38 2.32 6.79 9.33 9.22 9.56 11
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 11 20 51 127 188 245 390
Selling, General & Admin Expense		 2.44 5.11 13 26 38 54 86
Research & Development Expense		 8.44 15 38 101 150 191 304
Total Other Income / (Expense), net		 0.00 -7.40 -0.08 0.04 4.92 23 57
Interest & Investment Income		 0.00 0.00 0.21 0.10 4.98 24 57
Other Income / (Expense), net		 0.00 -0.02 -0.08 -0.06 -0.06 -0.59 -0.25
Basic Earnings per Share		 ($4.53) ($9.12) ($2.05) ($2.85) ($3.34) ($2.91) ($2.89)
Weighted Average Basic Shares Outstanding		 2.48M 2.71M 21.66M 41.43M 52.16M 73.01M 111.58M
Diluted Earnings per Share		 ($4.53) ($9.12) ($2.05) ($2.85) ($3.34) ($2.91) ($2.89)
Weighted Average Diluted Shares Outstanding		 2.48M 2.71M 21.66M 41.43M 52.16M 73.01M 111.58M
Weighted Average Basic & Diluted Shares Outstanding		 2.48M 2.71M 21.66M 41.43M 70.81M 79.72M 120.21M

Quarterly Income Statements for Avidity Biosciences

This table shows Avidity Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -44 -50 -52 -47 -52 -60 -69 -71 -80 -102
Consolidated Net Income / (Loss)		 -44 -50 -52 -47 -52 -60 -69 -71 -80 -102
Net Income / (Loss) Continuing Operations		 -44 -51 -52 -47 -52 -60 -69 -71 -80 -102
Total Pre-Tax Income 		-44 -50 -52 -47 -52 -60 -69 -71 -80 -102
Total Operating Income		 -45 -53 -58 -53 -59 -67 -77 -83 -98 -121
Total Gross Profit		 2.48 2.77 2.23 2.32 2.82 2.19 3.54 2.05 2.34 2.97
Total Revenue		 2.48 2.77 2.23 2.32 2.82 2.19 3.54 2.05 2.34 2.97
Operating Revenue		 2.48 2.77 2.23 2.32 2.82 2.19 3.54 2.05 2.34 2.97
Total Operating Expenses		 47 56 60 55 61 69 81 85 100 124
Selling, General & Admin Expense		 10 10 12 12 14 16 14 21 23 28
Research & Development Expense		 37 46 48 43 48 53 67 64 77 96
Total Other Income / (Expense), net		 1.33 2.75 5.20 5.61 6.27 6.30 8.33 12 18 19
Interest & Investment Income		 1.34 2.77 5.52 5.77 6.28 6.41 8.43 12 18 19
Other Income / (Expense), net		 -0.01 -0.02 -0.31 -0.16 -0.01 -0.11 -0.10 -0.12 -0.23 0.20
Basic Earnings per Share		 ($0.82) ($0.89) ($0.74) ($0.66) ($0.71) ($0.80) ($0.79) ($0.65) ($0.65) ($0.80)
Weighted Average Basic Shares Outstanding		 53.07M 52.16M 70.43M 71.39M 74.10M 73.01M 87.21M 106.93M 123.38M 111.58M
Diluted Earnings per Share		 ($0.82) ($0.89) ($0.74) ($0.66) ($0.71) ($0.80) ($0.79) ($0.65) ($0.65) ($0.80)
Weighted Average Diluted Shares Outstanding		 53.07M 52.16M 70.43M 71.39M 74.10M 73.01M 87.21M 106.93M 123.38M 111.58M
Weighted Average Basic & Diluted Shares Outstanding		 54.46M 70.81M 70.82M 74.10M 74.10M 79.72M 95.64M 109.80M 119.31M 120.21M

Annual Cash Flow Statements for Avidity Biosciences

This table details how cash moves in and out of Avidity Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -4.56 91 227 -1.01 20 -155 37
Net Cash From Operating Activities		 -9.66 2.49 -37 -95 -136 -119 -301
Net Cash From Continuing Operating Activities		 -9.66 2.49 -37 -95 -136 -119 -301
Net Income / (Loss) Continuing Operations		 -11 -25 -44 -118 -174 -212 -322
Consolidated Net Income / (Loss)		 -11 -25 -44 -118 -174 -212 -322
Depreciation Expense		 0.38 0.35 0.37 0.64 1.39 2.10 2.78
Amortization Expense		 0.07 0.07 0.01 0.18 -0.62 -11 -21
Non-Cash Adjustments To Reconcile Net Income		 0.43 7.45 4.60 18 30 41 55
Changes in Operating Assets and Liabilities, net		 0.65 19 2.26 4.63 7.07 61 -15
Net Cash From Investing Activities		 -0.05 -0.24 -7.79 -83 -190 -130 -854
Net Cash From Continuing Investing Activities		 -0.05 -0.24 -7.79 -83 -190 -130 -854
Purchase of Property, Plant & Equipment		 -0.05 -0.24 -1.09 -3.74 -2.82 -4.23 -7.07
Purchase of Investments		 0.00 0.00 -6.69 -85 -356 -461 -1,434
Sale and/or Maturity of Investments		 - 0.00 0.00 6.58 169 335 586
Net Cash From Financing Activities		 5.14 89 272 176 346 94 1,192
Net Cash From Continuing Financing Activities		 5.14 89 272 176 346 94 1,192
Issuance of Common Equity		 0.00 0.00 275 176 346 94 1,192

Quarterly Cash Flow Statements for Avidity Biosciences

This table details how cash moves in and out of Avidity Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 19 197 -222 35 -68 99 286 107 -206 -150
Net Cash From Operating Activities		 -32 -39 -49 -50 -37 17 -70 -65 -66 -100
Net Cash From Continuing Operating Activities		 -32 -39 -49 -50 -37 17 -70 -65 -66 -100
Net Income / (Loss) Continuing Operations		 -44 -50 -52 -47 -52 -60 -69 -71 -80 -102
Consolidated Net Income / (Loss)		 -44 -50 -52 -47 -52 -60 -69 -71 -80 -102
Depreciation Expense		 0.37 0.38 0.39 0.53 0.57 0.62 0.64 0.69 0.71 0.74
Amortization Expense		 -0.04 -0.80 -2.23 -2.84 -2.97 -3.24 -2.96 -4.48 -6.85 -7.17
Non-Cash Adjustments To Reconcile Net Income		 7.78 7.99 9.79 10 11 11 11 14 15 15
Changes in Operating Assets and Liabilities, net		 3.53 3.71 -4.53 -11 7.41 69 -10 -4.06 6.01 -6.16
Net Cash From Investing Activities		 11 -7.77 -196 46 -31 51 -33 -275 -482 -64
Net Cash From Continuing Investing Activities		 11 -7.77 -196 46 -31 51 -33 -275 -482 -64
Purchase of Property, Plant & Equipment		 0.11 -0.85 -1.82 -0.62 -0.92 -0.86 -0.92 -0.53 -1.70 -3.92
Purchase of Investments		 -54 -90 -251 -24 -132 -54 -142 -373 -622 -297
Sale and/or Maturity of Investments		 64 83 57 71 101 106 110 98 142 237
Net Cash From Financing Activities		 40 244 23 39 0.04 32 389 447 342 14
Net Cash From Continuing Financing Activities		 40 244 23 39 0.04 32 389 447 342 14
Issuance of Common Equity		 40 244 23 39 0.04 32 389 447 342 14

Annual Balance Sheets for Avidity Biosciences

This table presents Avidity Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 97 334 428 639 629 1,564
Total Current Assets		 96 332 411 623 611 1,542
Cash & Equivalents		 95 321 320 340 185 220
Short-Term Investments		 0.00 6.68 85 270 410 1,282
Prepaid Expenses		 1.10 3.54 5.60 12 16 41
Plant, Property, & Equipment, net		 0.63 1.47 4.81 6.25 8.38 13
Total Noncurrent Assets		 0.60 0.30 12 9.60 8.87 8.94
Other Noncurrent Operating Assets		 0.60 0.30 12 9.60 8.87 8.94
Total Liabilities & Shareholders' Equity		 97 334 428 639 629 1,564
Total Liabilities		 28 28 46 61 128 139
Total Current Liabilities		 10 15 30 52 81 98
Accounts Payable		 2.31 7.75 14 33 34 70
Current Deferred Revenue		 3.84 3.69 4.86 5.04 28 21
Current Employee Benefit Liabilities		 1.31 3.15 8.94 11 14 3.66
Other Current Liabilities		 - - 1.77 3.11 3.64 3.84
Total Noncurrent Liabilities		 17 13 16 8.82 47 41
Noncurrent Deferred Revenue		 15 12 6.53 1.24 41 38
Other Noncurrent Operating Liabilities		 0.44 0.94 9.96 7.58 6.21 2.96
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -65 306 381 578 501 1,425
Total Preferred & Common Equity		 -65 306 381 578 501 1,425
Total Common Equity		 -65 306 381 578 501 1,425
Common Stock		 -43 373 566 939 1,071 2,315
Retained Earnings		 -22 -67 -185 -359 -571 -893
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.01 -0.19 -2.70 0.13 2.90

Quarterly Balance Sheets for Avidity Biosciences

This table presents Avidity Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 431 614 611 573 951 1,347 1,641
Total Current Assets		 414 597 595 555 934 1,329 1,622
Cash & Equivalents		 144 119 154 86 471 576 370
Short-Term Investments		 262 468 423 457 444 723 1,218
Prepaid Expenses		 8.92 11 18 13 19 30 33
Plant, Property, & Equipment, net		 6.04 7.85 7.78 8.13 8.66 8.50 9.49
Total Noncurrent Assets		 9.79 8.98 8.47 9.55 8.35 10 9.41
Other Noncurrent Operating Assets		 9.79 8.98 8.47 9.55 8.35 10 9.41
Total Liabilities & Shareholders' Equity		 431 614 611 573 951 1,347 1,641
Total Liabilities		 54 55 52 56 121 126 137
Total Current Liabilities		 43 48 45 49 75 84 91
Accounts Payable		 26 34 32 32 37 41 50
Current Deferred Revenue		 5.45 5.06 3.81 1.97 26 27 20
Current Employee Benefit Liabilities		 7.75 6.01 6.53 11 7.80 13 18
Other Current Liabilities		 3.09 3.13 3.15 3.60 3.73 3.77 3.80
Total Noncurrent Liabilities		 11 6.98 6.36 6.98 46 42 46
Noncurrent Deferred Revenue		 2.71 0.00 0.00 0.00 40 38 42
Other Noncurrent Operating Liabilities		 - 6.98 6.36 - - 4.62 3.80
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 377 559 559 517 831 1,221 1,503
Total Preferred & Common Equity		 377 559 559 517 831 1,221 1,503
Total Common Equity		 377 559 559 517 831 1,221 1,503
Common Stock		 689 971 1,020 1,030 1,471 1,932 2,287
Retained Earnings		 -308 -411 -458 -510 -640 -710 -791
Accumulated Other Comprehensive Income / (Loss)		 -3.46 -1.53 -2.67 -1.88 -0.46 -0.45 7.10

Annual Metrics and Ratios for Avidity Biosciences

This table displays calculated financial ratios and metrics derived from Avidity Biosciences' official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 511.87% 192.67% 37.41% -1.09% 3.64% 13.99%
EBITDA Growth		 0.00% -68.57% -159.75% -166.76% -51.92% -37.69% -62.15%
EBIT Growth		 0.00% -65.24% -155.68% -166.31% -51.52% -31.97% -60.54%
NOPAT Growth		 0.00% -65.10% -155.46% -166.62% -51.56% -31.68% -60.84%
Net Income Growth		 0.00% -120.52% -79.33% -166.06% -47.44% -21.97% -51.87%
EPS Growth		 0.00% -101.32% 77.52% -39.02% -17.19% 12.87% 0.69%
Operating Cash Flow Growth		 0.00% 125.79% -1,590.64% -155.44% -43.72% 12.63% -152.70%
Free Cash Flow Firm Growth		 0.00% 0.00% -443.06% -176.16% -44.26% 11.75% -175.10%
Invested Capital Growth		 0.00% 0.00% -8.23% -7.78% -35.41% -189.68% 19.08%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% -3.02% 11.04% -5.68% 7.71%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -23.18% -9.43% -6.89% -16.98%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% -23.25% -8.91% -6.11% -16.58%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% -23.23% -8.94% -6.09% -16.71%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% -23.25% -7.36% -4.93% -14.91%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -630.77% -1.83% 3.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -27.71% -16.09% -10.52% 31.87% -63.07%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -3.75% 34.80% -76.84%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% -32.84% -58.26% -421.54% 10.18%
Profitability Metrics		 - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -2,649.60% -729.97% -647.86% -1,257.72% -1,931.90% -2,566.58% -3,651.05%
Operating Margin		 -2,769.92% -747.39% -652.38% -1,265.83% -1,939.65% -2,464.41% -3,477.43%
EBIT Margin		 -2,769.92% -748.04% -653.48% -1,266.49% -1,940.26% -2,470.63% -3,479.71%
Profit (Net Income) Margin		 -2,959.37% -1,066.58% -653.53% -1,265.38% -1,886.33% -2,219.87% -2,957.71%
Tax Burden Percent		 106.84% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 142.58% 100.01% 99.91% 97.22% 89.85% 85.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -35.66% -23.62% -34.32% -36.27% -39.34% -33.47%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -17.90% -20.59% -31.02% -33.57% -37.27% -34.59%
Return on Assets (ROA)		 0.00% -25.52% -20.59% -30.99% -32.63% -33.49% -29.40%
Return on Common Equity (ROCE)		 0.00% 33.60% -15.15% -34.32% -36.27% -39.34% -33.47%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 37.84% -14.48% -30.94% -30.10% -42.38% -22.62%
Net Operating Profit after Tax (NOPAT)		 -7.35 -12 -31 -83 -125 -165 -265
NOPAT Margin		 -1,938.94% -523.17% -456.67% -886.08% -1,357.75% -1,725.09% -2,434.20%
Net Nonoperating Expense Percent (NNEP)		 0.00% -27.99% -6.38% -9.64% -9.60% -7.84% -5.44%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -21.66% -32.93% -18.61%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 644.06% 220.44% 198.35% 280.88% 409.07% 566.84% 791.41%
R&D to Revenue		 2,225.86% 626.95% 554.03% 1,084.95% 1,630.57% 1,997.57% 2,786.02%
Operating Expenses to Revenue		 2,869.92% 847.39% 752.38% 1,365.83% 2,039.65% 2,564.41% 3,577.43%
Earnings before Interest and Taxes (EBIT)		 -10 -17 -44 -118 -179 -236 -379
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -10 -17 -44 -117 -178 -245 -398
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 3.13 2.92 2.09 1.34 2.43
Price to Tangible Book Value (P/TBV)		 0.00 0.00 3.13 2.92 2.09 1.34 2.43
Price to Revenue (P/Rev)		 395.78 64.68 141.11 119.53 131.02 70.15 318.39
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 83.95 92.76 76.05 64.81 7.87 180.60
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 78.19 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 22.80 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.07 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.03 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.30 -1.11 -1.07 -1.06 -1.12 -1.09
Leverage Ratio		 0.00 1.40 1.15 1.11 1.11 1.17 1.14
Compound Leverage Factor		 0.00 1.99 1.15 1.11 1.08 1.06 0.97
Debt to Total Capital		 0.00% 6.15% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 3.75% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 2.39% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 182.28% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -88.43% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 -0.27 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 5.32 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 -0.10 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.37 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 7.42 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 -0.15 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 3.44 21.21 14.07 11.32 1.67 14.50
Noncontrolling Interest Sharing Ratio		 0.00% 194.22% 35.87% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 0.00 9.35 22.74 13.86 12.00 7.58 15.73
Quick Ratio		 0.00 9.24 22.50 13.67 11.77 7.38 15.32
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 8.54 -29 -81 -117 -103 -283
Operating Cash Flow to CapEx		 -19,704.08% 1,059.57% -3,398.99% -2,535.11% -4,827.06% -2,816.08% -4,258.00%
Free Cash Flow to Firm to Interest Expense		 0.00 1.16 -140.16 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.34 -177.59 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.31 -182.82 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.02 0.03 0.02 0.02 0.02 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 3.68 6.47 2.97 1.67 1.31 1.04
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 -21 -22 -24 -33 -95 -77
Invested Capital Turnover		 0.00 -0.22 -0.32 -0.40 -0.33 -0.15 -0.13
Increase / (Decrease) in Invested Capital		 0.00 -21 -1.70 -1.74 -8.54 -62 18
Enterprise Value (EV)		 0.00 195 630 709 598 75 1,968
Market Capitalization		 150 150 958 1,115 1,209 671 3,470
Book Value per Share		 $0.00 ($24.09) $8.16 $8.13 $10.61 $6.76 $11.94
Tangible Book Value per Share		 $0.00 ($24.09) $8.16 $8.13 $10.61 $6.76 $11.94
Total Capital		 0.00 74 306 381 578 501 1,425
Total Debt		 0.00 4.54 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 1.77 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -90 -328 -406 -611 -595 -1,501
Capital Expenditures (CapEx)		 0.05 0.24 1.09 3.74 2.82 4.23 7.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -6.36 -11 -24 -40 -65 -57
Debt-free Net Working Capital (DFNWC)		 0.00 88 317 381 571 531 1,444
Net Working Capital (NWC)		 0.00 85 317 381 571 531 1,444
Net Nonoperating Expense (NNE)		 3.87 13 13 35 49 47 57
Net Nonoperating Obligations (NNO)		 0.00 -90 -329 -406 -611 -595 -1,501
Total Depreciation and Amortization (D&A)		 0.46 0.42 0.38 0.82 0.77 -9.17 -19
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -274.43% -162.81% -257.99% -430.32% -677.03% -525.14%
Debt-free Net Working Capital to Revenue		 0.00% 3,803.97% 4,672.03% 4,090.53% 6,190.74% 5,550.49% 13,253.85%
Net Working Capital to Revenue		 0.00% 3,684.35% 4,672.03% 4,090.53% 6,190.74% 5,550.49% 13,253.85%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($2.05) ($2.85) ($3.34) ($2.91) ($2.89)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 37.58M 47.75M 52.16M 73.01M 111.58M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($2.05) ($2.85) ($3.34) ($2.91) ($2.89)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 37.58M 47.75M 52.16M 73.01M 111.58M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($2.05) ($2.85) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 21.66M 41.43M 70.81M 79.72M 120.21M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.35 -12 -31 -83 -125 -165 -265
Normalized NOPAT Margin		 -1,938.94% -523.17% -456.67% -886.08% -1,357.75% -1,725.09% -2,434.20%
Pre Tax Income Margin		 -2,769.92% -1,066.58% -653.53% -1,265.38% -1,886.33% -2,219.87% -2,957.71%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 -2.35 -212.21 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 -1.64 -148.30 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 -2.38 -217.44 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 -1.67 -153.52 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% -0.43% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -0.43% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Avidity Biosciences

This table displays calculated financial ratios and metrics derived from Avidity Biosciences' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 14.75% 49.51% 24.40% 6.34% 13.54% -20.80% 58.67% -11.70% -17.10% 35.57%
EBITDA Growth		 -53.35% -40.11% -75.70% -20.01% -36.83% -29.46% -33.23% -57.02% -71.21% -83.12%
EBIT Growth		 -53.46% -37.94% -67.93% -14.03% -30.48% -25.55% -33.46% -56.72% -67.75% -80.69%
NOPAT Growth		 -53.45% -38.08% -67.14% -13.68% -30.48% -25.40% -34.01% -56.98% -67.39% -81.28%
Net Income Growth		 -48.93% -30.96% -53.04% -2.92% -20.09% -19.76% -31.42% -50.54% -53.55% -69.18%
EPS Growth		 -20.59% -7.23% -4.23% 28.26% 13.41% 10.11% -6.76% 1.52% 8.45% 0.00%
Operating Cash Flow Growth		 -53.78% -49.49% -65.57% -40.12% -15.12% 142.11% -43.73% -30.51% -78.35% -705.24%
Free Cash Flow Firm Growth		 -24.22% -13.77% -39.66% -8.94% -50.27% 152.98% 94.57% 108.16% 96.29% -775.27%
Invested Capital Growth		 -13.66% -35.41% -28.19% -12.76% 12.10% -189.68% -190.50% -350.27% -369.86% 19.08%
Revenue Q/Q Growth		 13.96% 11.56% -19.36% 3.72% 21.68% -22.18% 61.56% -42.28% 14.23% 27.27%
EBITDA Q/Q Growth		 2.85% -20.29% -11.35% 7.77% -10.76% -13.81% -14.59% -8.70% -20.77% -21.74%
EBIT Q/Q Growth		 2.94% -18.47% -8.77% 8.83% -11.07% -14.00% -15.62% -7.06% -18.88% -22.79%
NOPAT Q/Q Growth		 2.96% -18.46% -8.21% 8.62% -11.38% -13.85% -15.65% -7.05% -18.77% -23.29%
Net Income Q/Q Growth		 4.58% -15.76% -3.81% 10.25% -11.34% -15.44% -13.92% -2.81% -13.57% -27.19%
EPS Q/Q Growth		 10.87% -8.54% 16.85% 10.81% -7.58% -12.68% 1.25% 17.72% 0.00% -23.08%
Operating Cash Flow Q/Q Growth		 10.09% -22.62% -24.95% -1.72% 26.13% 144.85% -526.52% 7.64% -0.94% -52.21%
Free Cash Flow Firm Q/Q Growth		 9.53% 0.87% -19.42% -1.72% -24.80% 134.95% -112.24% 252.82% -156.79% -6,254.61%
Invested Capital Q/Q Growth		 -34.28% -58.26% 16.13% 36.74% -4.68% -421.54% 15.89% 1.94% -9.23% 10.18%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -1,797.34% -1,937.92% -2,675.77% -2,379.40% -2,166.00% -3,167.81% -2,246.88% -4,231.30% -4,473.54% -4,279.04%
Operating Margin		 -1,810.19% -1,922.17% -2,579.31% -2,272.63% -2,080.38% -3,043.46% -2,178.58% -4,040.39% -4,200.94% -4,069.59%
EBIT Margin		 -1,810.68% -1,922.82% -2,593.37% -2,279.62% -2,080.84% -3,048.24% -2,181.43% -4,046.06% -4,210.87% -4,062.83%
Profit (Net Income) Margin		 -1,756.61% -1,822.72% -2,346.35% -2,030.44% -1,857.98% -2,756.18% -1,943.41% -3,461.76% -3,441.70% -3,439.49%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 97.01% 94.79% 90.47% 89.07% 89.29% 90.42% 89.09% 85.56% 81.73% 84.66%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -41.99% -36.27% -41.12% -41.45% -45.22% -39.34% -32.91% -28.36% -27.76% -33.47%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -35.12% -33.26% -48.41% -43.31% -42.03% -45.99% -30.29% -43.80% -38.48% -40.39%
Return on Assets (ROA)		 -34.08% -31.53% -43.80% -38.58% -37.53% -41.58% -26.99% -37.47% -31.46% -34.19%
Return on Common Equity (ROCE)		 -41.99% -36.27% -41.12% -41.45% -45.22% -39.34% -32.91% -28.36% -27.76% -33.47%
Return on Equity Simple (ROE_SIMPLE)		 -42.99% 0.00% -34.38% -34.60% -39.08% 0.00% -27.52% -20.68% -18.66% 0.00%
Net Operating Profit after Tax (NOPAT)		 -31 -37 -40 -37 -41 -47 -54 -58 -69 -85
NOPAT Margin		 -1,267.14% -1,345.52% -1,805.52% -1,590.84% -1,456.26% -2,130.42% -1,525.00% -2,828.27% -2,940.66% -2,848.72%
Net Nonoperating Expense Percent (NNEP)		 -3.00% -2.60% -2.46% -2.11% -2.43% -2.28% -1.98% -1.38% -1.10% -1.68%
Return On Investment Capital (ROIC_SIMPLE)		 - -6.45% - - - -9.33% - - - -5.94%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 406.69% 375.01% 540.26% 530.14% 487.19% 735.02% 392.27% 1,013.74% 996.28% 953.18%
R&D to Revenue		 1,503.51% 1,647.17% 2,139.05% 1,842.49% 1,693.19% 2,408.44% 1,886.31% 3,126.65% 3,304.67% 3,216.41%
Operating Expenses to Revenue		 1,910.19% 2,022.17% 2,679.31% 2,372.63% 2,180.38% 3,143.46% 2,278.58% 4,140.39% 4,300.94% 4,169.59%
Earnings before Interest and Taxes (EBIT)		 -45 -53 -58 -53 -59 -67 -77 -83 -98 -121
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -45 -54 -60 -55 -61 -69 -80 -87 -105 -127
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 2.26 2.09 1.94 1.40 0.91 1.34 2.28 3.20 3.35 2.43
Price to Tangible Book Value (P/TBV)		 2.26 2.09 1.94 1.40 0.91 1.34 2.28 3.20 3.35 2.43
Price to Revenue (P/Rev)		 102.47 131.02 112.49 80.14 46.64 70.15 173.97 368.60 498.49 318.39
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 54.61 64.81 51.81 21.31 0.00 7.87 90.21 246.03 341.46 180.60
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.02 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.00 0.00
Long-Term Debt to Equity		 0.02 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.00 0.00
Financial Leverage		 -1.05 -1.06 -1.05 -1.04 -1.04 -1.12 -1.08 -1.05 -1.05 -1.09
Leverage Ratio		 1.11 1.11 1.11 1.11 1.12 1.17 1.13 1.10 1.10 1.14
Compound Leverage Factor		 1.08 1.05 1.00 0.98 1.00 1.06 1.00 0.94 0.90 0.96
Debt to Total Capital		 2.13% 0.00% 0.00% 0.00% 1.33% 0.00% 0.65% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 2.13% 0.00% 0.00% 0.00% 1.33% 0.00% 0.65% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 97.87% 100.00% 100.00% 100.00% 98.67% 100.00% 99.35% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.05 0.00 0.00 0.00 -0.03 0.00 -0.02 0.00 0.00 0.00
Net Debt to EBITDA		 2.44 0.00 0.00 0.00 2.33 0.00 3.43 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.05 0.00 0.00 0.00 -0.03 0.00 -0.02 0.00 0.00 0.00
Debt to NOPAT		 -0.07 0.00 0.00 0.00 -0.04 0.00 -0.03 0.00 0.00 0.00
Net Debt to NOPAT		 3.46 0.00 0.00 0.00 3.45 0.00 5.10 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.07 0.00 0.00 0.00 -0.04 0.00 -0.03 0.00 0.00 0.00
Altman Z-Score		 9.25 11.97 11.68 8.89 4.59 2.55 9.30 18.72 22.28 15.04
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 9.71 12.00 12.42 13.14 11.40 7.58 12.47 15.78 17.76 15.73
Quick Ratio		 9.51 11.77 12.19 12.74 11.14 7.38 12.22 15.43 17.39 15.32
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -29 -29 -34 -35 -44 15 -1.86 2.85 -1.62 -103
Operating Cash Flow to CapEx		 0.00% -4,610.47% -2,690.49% -8,007.56% -3,986.02% 1,912.05% -7,691.80% -12,241.81% -3,850.65% -2,550.33%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.02 0.02 0.02 0.02 0.02 0.02 0.01 0.01 0.01 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.79 1.67 1.50 1.41 1.43 1.31 1.32 1.30 1.15 1.04
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -21 -33 -27 -17 -18 -95 -80 -78 -85 -77
Invested Capital Turnover		 -0.43 -0.33 -0.40 -0.60 -0.52 -0.15 -0.20 -0.22 -0.20 -0.13
Increase / (Decrease) in Invested Capital		 -2.48 -8.54 -6.02 -1.96 2.50 -62 -52 -61 -67 18
Enterprise Value (EV)		 454 598 501 209 -63 75 981 2,608 3,455 1,968
Market Capitalization		 851 1,209 1,087 785 473 671 1,891 3,907 5,043 3,470
Book Value per Share		 $7.23 $10.61 $7.89 $7.90 $6.98 $6.76 $9.53 $12.77 $13.69 $11.94
Tangible Book Value per Share		 $7.23 $10.61 $7.89 $7.90 $6.98 $6.76 $9.53 $12.77 $13.69 $11.94
Total Capital		 385 578 559 559 524 501 836 1,221 1,503 1,425
Total Debt		 8.19 0.00 0.00 0.00 6.98 0.00 5.42 0.00 0.00 0.00
Total Long-Term Debt		 8.19 0.00 0.00 0.00 6.98 0.00 5.42 0.00 0.00 0.00
Net Debt		 -398 -611 -586 -577 -536 -595 -910 -1,299 -1,589 -1,501
Capital Expenditures (CapEx)		 -0.11 0.85 1.82 0.62 0.92 0.86 0.92 0.53 1.70 3.92
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -34 -40 -37 -27 -36 -65 -56 -54 -58 -57
Debt-free Net Working Capital (DFNWC)		 372 571 549 549 507 531 860 1,245 1,531 1,444
Net Working Capital (NWC)		 372 571 549 549 507 531 860 1,245 1,531 1,444
Net Nonoperating Expense (NNE)		 12 13 12 10 11 14 15 13 12 18
Net Nonoperating Obligations (NNO)		 -398 -611 -586 -577 -536 -595 -910 -1,299 -1,589 -1,501
Total Depreciation and Amortization (D&A)		 0.33 -0.42 -1.84 -2.31 -2.40 -2.62 -2.32 -3.79 -6.14 -6.43
Debt-free, Cash-free Net Working Capital to Revenue		 -409.31% -430.32% -385.41% -277.68% -353.31% -677.03% -518.44% -513.79% -573.89% -525.14%
Debt-free Net Working Capital to Revenue		 4,475.72% 6,190.74% 5,682.70% 5,605.00% 4,999.71% 5,550.49% 7,907.26% 11,742.51% 15,128.33% 13,253.85%
Net Working Capital to Revenue		 4,475.72% 6,190.74% 5,682.70% 5,605.00% 4,999.71% 5,550.49% 7,907.26% 11,742.51% 15,128.33% 13,253.85%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.82) ($0.89) ($0.74) ($0.66) ($0.71) ($0.80) ($0.79) ($0.65) ($0.65) ($0.80)
Adjusted Weighted Average Basic Shares Outstanding		 53.07M 52.16M 70.43M 71.39M 74.10M 73.01M 87.21M 106.93M 123.38M 111.58M
Adjusted Diluted Earnings per Share		 ($0.82) ($0.89) ($0.74) ($0.66) ($0.71) ($0.80) ($0.79) ($0.65) ($0.65) ($0.80)
Adjusted Weighted Average Diluted Shares Outstanding		 53.07M 52.16M 70.43M 71.39M 74.10M 73.01M 87.21M 106.93M 123.38M 111.58M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 54.46M 70.81M 70.82M 74.10M 74.10M 79.72M 95.64M 109.80M 119.31M 120.21M
Normalized Net Operating Profit after Tax (NOPAT)		 -31 -37 -40 -37 -41 -47 -54 -58 -69 -85
Normalized NOPAT Margin		 -1,267.14% -1,345.52% -1,805.52% -1,590.84% -1,456.26% -2,130.42% -1,525.00% -2,828.27% -2,940.66% -2,848.72%
Pre Tax Income Margin		 -1,756.61% -1,822.72% -2,346.35% -2,030.44% -1,857.98% -2,756.18% -1,943.41% -3,461.76% -3,441.70% -3,439.49%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Avidity Biosciences' Financials

When does Avidity Biosciences's fiscal year end?

According to the most recent income statement we have on file, Avidity Biosciences' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Avidity Biosciences' net income changed over the last 6 years?

Avidity Biosciences' net income appears to be on an upward trend, with a most recent value of -$322.30 million in 2024, rising from -$11.22 million in 2018. The previous period was -$212.22 million in 2023. See Avidity Biosciences' forecast for analyst expectations on what’s next for the company.

What is Avidity Biosciences's operating income?
Avidity Biosciences's total operating income in 2024 was -$378.94 million, based on the following breakdown:
  • Total Gross Profit: $10.90 million
  • Total Operating Expenses: $389.83 million
How has Avidity Biosciences revenue changed over the last 6 years?

Over the last 6 years, Avidity Biosciences' total revenue changed from $379 thousand in 2018 to $10.90 million in 2024, a change of 2,775.2%.

How much debt does Avidity Biosciences have?

Avidity Biosciences' total liabilities were at $138.94 million at the end of 2024, a 8.7% increase from 2023, and a 404.4% increase since 2019.

How much cash does Avidity Biosciences have?

In the past 5 years, Avidity Biosciences' cash and equivalents has ranged from $94.58 million in 2019 to $340.40 million in 2022, and is currently $219.87 million as of their latest financial filing in 2024.

How has Avidity Biosciences' book value per share changed over the last 6 years?

Over the last 6 years, Avidity Biosciences' book value per share changed from 0.00 in 2018 to 11.94 in 2024, a change of 1,194.3%.


Related Companies

This page (NASDAQ:RNA) was last updated on 5/6/2025 by MarketBeat.com Staff
From Our Partners
Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...
American Hartford Gold | Sponsored
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...
Porter & Company | Sponsored
Shocking AI play that’s beats Nvidia by a country mile
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...
Timothy Sykes | Sponsored
Altucher: Turn $900 into $108,000 in just 12 months?
We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.
Paradigm Press | Sponsored
Most traders are panicking. We’re cashing in
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....
Crypto Swap Profits | Sponsored
Trump’s Bitcoin Reserve is No Accident…
Crypto policy is changing fast… Smart investors are positioning themselves to benefit. And it's all happeni...
Crypto 101 Media | Sponsored
Elon Musk is all in on these robots …
Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...
Weiss Ratings | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored